Experience

Adelphi Values has an experienced global team of qualitative researchers, health economists, statisticians, creative scientists, clinicians and strategists with industry experience, who truly understand the need to develop evidence and communicate value throughout the product lifecycle.

Below is a selection of our projects, presented according to therapeutic or strategic/methodological area. It is not exhaustive, and we would be happy to provide further information on request.

Immune thrombocytopenic purpura

  • Analysis and reporting on immune thrombocytopenic purpura
  • Caregiver interviews to support content validity of an ObsRO in a paediatric population with chronic immune thrombocytopenic purpura
  • Palatability and acceptability of a treatment in paediatric populations with chronic immune thrombocytopenic purpura
  • Development of a scoring algorithm for an acceptability and palatability questionnaire in chronic immune thrombocytopenic purpura
  • Literature review and qualitative research to support the content validation of the immune thrombocytopenia quality of life index

Immunology

  • Biosimilar payer communications in immunology
  • Development of a payer value deck in immunology in ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis
  • Payer value slides for a varicella vaccine
  • Payer value slides for immunology biosimilars
  • Payer value slide deck in muscle relaxation management
  • Payer value deck for an MMR and varicella vaccine
  • Payer focused value communication on rheumatoid arthritis
  • Payer material development for vaccines in hepatitis A, rotavirus gastroenteritis (RVGE), shingles, varicella and pneumococcal disease
  • Payer evidence dossier for a new psoriasis treatment
  • Payer value proposition in rheumatoid arthritis
  • Communications package in hereditary angioedema
  • Patient support programme, payer communication tool and briefing pack in immunology
  • Frequently asked questions deck in juvenile idiopathic arthritis
  • Frequently asked questions to support the introduction of a new biosimilar in immunology
  • Frequently asked questions for biosimilar policy in immunology
  • Frequently asked questions on an immunology biosimilar for rheumatoid arthritis
  • Workshop and FAQ development in immunology in ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis
  • Literature and content searches for global value dossiers in dermatology and immunology
  • Structured literature review for allergy immunotherapy, including medication adherence compared to other treatments
  • Strategic literature review and gap analysis in systemic lupus erythematosus and lupus nephritis
  • Communication of a literature review on systemic lupus erythematosus and lupus nephritis
  • Literature review of unmet need in rheumatoid arthritis
  • Literature review and update to budget impact model in an immunology biosimilar
  • Targeted literature review in psoriatic arthritis patients with concomitant moderate to severe psoriasis
  • Health economics training and model training in immunology
  • Interactive model in immunology
  • Economic workshop in immunology
  • Economic evaluation of a workplace influenza vaccination in Russia
  • Total Brand FAQ deck and Total Brand Workshop in rheumatoid arthritis, prostate-specific antigen (PsA), psoriasis, ulcerative colitis, Crohn’s disease and ankylosing spondylitis
  • Updates to a US budget impact model for an immunology biosimilar
  • AMCP dossier, budget impact model and global value dossier development in immunology
  • Update for a core value dossier in uveitis
  • Early global value dossiers for a new monoclonal antibody in Crohn’s disease and psoriasis
  • Global value dossiers and budget impact models for biosimilars in ankylosing spondylitis, Crohn’s disease, inflammatory bowel disease, osteoarthritis, psoriasis and rheumatoid arthritis
  • Update to an AMCP dossier for an immunology biosimilar
  • Updates to a global value dossier, AMCP dossier and budget impact model on a rheumatoid arthritis biosimilar
  • Two competitor review decks in psoriatic arthritis and ankylosing spondylitis
  • Two competitor reviews in psoriatic arthritis
  • Competitor value story in rheumatoid arthritis
  • Competitor value story in psoriatic arthritis
  • Competitor review of two JAK inhibitors in rheumatoid arthritis
  • Kidney transplant pricing research
  • Development of launch materials in ankylosing spondylitis and psoriatic arthritis
  • HTA strategy in immunology (ankylosing spondylitis and psoriatic arthritis)
  • Cross-therapy area value proposition alignment in immunology
  • Originator vs. biosimilar value proposition update in immunology
  • Regulatory support on SMC questions on psoriatic arthritis work
  • Product value insight evaluation and strategy in atopic dermatitis
  • Core value dossier on psoriatic arthritis
  • Identification of PRO measures suitable for implementation in phase III oncology and immunotherapy trials
  • Analysis of a PRO and resource utilization in systemic lupus erythematosus
  • Critical review of PRO instruments in systemic lupus erythematosus and fatigue and pain in rheumatic disease
  • Review of PROs in systemic sclerosis/scleroderma
  • Development of posters on the analysis of a PRO and resource utilization in systemic lupus erythematosus
  • Patient focused outcomes in amyloidosis: Exit interviews to capture the patient experience of systemic amyloidosis, treatment and clinical trial participation
  • Translation and linguistic validation of clinician assessments in ACEI-Angioedema
  • Communications on clinician assessments in ACEI-Angioedema
  • Measurement strategy to demonstrate efficacy of medical devices in patients with pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumour (dTGCT)
  • Strategic consultancy on physician attitudes and preferences regarding adult vaccinations
  • Regulatory support for the validation of a questionnaire for influenza vaccination
  • Demonstrating the value of antibiotic resistance testing software
  • Modification of the Eosinophilic Esophagitis Activity Index (EEsAI)

Infertility

  • Development of a value dossier, health economic model and literature review in an infertility biosimilar to support pricing and reimbursement submissions in 15 EU countries
  • Workshop on the EU price strategy for a recombinant follicle stimulating hormone used for the treatment of infertility
  • Conference presentation of health economic data on infertility treatment
  • Pricing updates in Europe for a biosimilar hormone treatment for female infertility
  • Advisory board with two payers to appraise an infertility product for reimbursement
  • Value story and communications for an infertility study

Influenza

  • Upgrade of current model-structure and sensitivity analysis in influenza
  • Adaptation of a cost effectiveness model for an influenza vaccine for Germany, Austria and Mexico
  • Two manuscripts on an influenza vaccine for patients at risk and patients over 65 years old in France
  • Conference poster on the cost effectiveness of adjuvant influenza vaccination in France
  • Update of a value dossier on an influenza vaccine
  • Cost-effectiveness analysis of an influenza vaccine
  • Modification of the SIR dynamic model to the SEIR model for the USA and Italy
  • Modelling of influenza coverage rates
  • Communication of influenza coverage rates within the European Union
  • Book chapter written on the economics of influenza
  • Review of influenza vaccine uptake data
  • Updating an economic model of influenza vaccination (phase 1) – update of a model in patients aged over 65 years in France and the UK
  • Economic evaluation of a workplace influenza vaccination in Russia
  • Communication of the economics of an influenza vaccine
  • Interactive model on influenza
  • Adaptation of an influenza vaccine model to Belgium
  • Positioning paper on influenza
  • Economic value dossiers for influenza vaccines in a) an unprimed paediatric population and b) a primed school age population (intranasal delivery) including literature review, gap analysis and recommendations
  • Literature research and reporting on epidemiology and the economic burden of influenza B in Japan
  • Modification of a SIR dynamic model to a SEIR model for the US and Italy
  • Dynamic model to inform internal decision making regarding pandemic influenza
  • Regulatory support for the validation of a questionnaire for influenza vaccination

Influenza vaccines

  • Economic value dossiers for influenza vaccines in a) an unprimed paediatric population and b) a primed school age population (intranasal delivery) including literature review, gap analysis and recommendations
  • Communications package for an influenza vaccine
  • Communication of the economics of an influenza vaccine
  • Two manuscripts on an influenza vaccine for patients at risk and patients over 65 years old in France
  • Review of influenza vaccine uptake data
  • Updating an economic model of influenza vaccination (phase 1) – update of a model in patients aged over 65 years in France and the UK
  • Economic evaluation of a workplace influenza vaccination in Russia
  • Cost-effectiveness analysis of an influenza vaccine
  • Adaptation of a cost effectiveness model for an influenza vaccine for Germany, Austria and Mexico
  • Conference poster on the cost effectiveness of adjuvant influenza vaccination in France
  • Adaptation of an influenza vaccine model to Belgium
  • Regulatory support for the validation of a questionnaire for influenza vaccination

Insomnia and sleep disorders

  • Survey of the impact of allergy on sleep (including literature review and HCP interviews)
  • Value communication support for an insomnia study
  • Value communication support for a systematic literature review in insomnia
  • Global value dossier and AMCP dossier in insomnia
  • Systematic literature review of real world evidence in insomnia
  • Advisory panel in insomnia
  • Targeted literature review in Alzheimer’s disease and associated insomnia
  • Review of PROs in insomnia
  • Cognitive debriefing of the daytime insomnia symptom scale and FDA support
  • Strategic consulting in insomnia
  • Validation of a primary insomnia functioning questionnaire
  • PRO strategy in insomnia
  • Manuscripts on the development and validation of the Sleep Impact Scale (SIS) in insomnia
  • Support on translation of the SIS in insomnia
  • Communications on the SIS in insomnia
  • Support on the adaptation of the SIS into three languages
  • Support on linguistic validation of the SIS in insomnia
  • Investigator meeting, review and presentation of slides on the Functional Outcomes of Sleep Questionnaire (FOSQ) and Work Limitation Questionnaire (WLQ)
  • Validation of the FOSQ in insomnia
  • Development of a conceptual framework and endpoint model in insomnia, plus qualitative patient interviews to confirm the validity of the conceptual framework and the psychometric validation of the final conceptual framework
  • Consultation on study design and interpretation of data on insomnia
  • Advisory panel in sleep disorders
  • Quality of life questionnaire in sleep disorders
  • Modification to the Sleep Impact Questionnaire following FDA review
  • Validation and linguistic adaptation of a sleep questionnaire
  • Linguistic validation of the Fatigue Impact Scale (FIS) into Argentinean Spanish, Austrian German, South African English, Norwegian and Afrikaans
  • Evaluation of the potential for a satisfaction claim for sleep disorders
  • Development of a PRO instrument for measuring mood swings and sleep problems resulting from vasomotor symptoms during the menopause
  • Evaluation of existing documentation and recommendations for psychometrically validating the modified Daytime Insomnia Symptom Scale (mDISS)
  • Scenario model in sleep disorders
  • Development of a sleep measure in different conditions
  • Report of sleep problems in fibromyalgia
  • Content validation of the modified Daytime Insomnia Symptom Scale (DISS) and the Sleep Impact Questionnaire event log
  • Manuscript on validation and efficacy results in insomnia

Interstitial cystitis

  • Literature review on interstitial cystitis
  • Development of a PRO for interstitial cystitis
  • Identification of cut-points to allow a newly developed interstitial cystitis symptom PRO to be used to screen patients entering a clinical trial and to assess the psychometric properties of the interstitial cystitis
  • Development of a manuscript on the Painful Bladder/Interstitial Cystitis Symptom Score (PBIC-SS) questionnaire
  • Revision of a manuscript on the PBIC-SS questionnaire and submission to a peer-reviewed journal

Interstitial lung disease

  • Consulting to help inform a PRO strategy for pulmonary hypertension in interstitial lung disease (PH-ILD)
  • Brief literature review to inform endpoint strategy recommendations for interstitial lung disease in systemic sclerosis (SSc-ILD)

Irritable bowel syndrome

  • Literature review of PROs and endpoints of pain in irritable bowel syndrome (IBS)
  • Literature review and manuscript on IBS
  • Patient interviews and qualitative work on IBS
  • Analysis of focus group data in IBS
  • Productivity workshop in IBS
  • Focus groups in IBS
  • Consulting for PROs for a treatment used in IBS
  • Prospective outcomes study in IBS
  • PRO strategy in generalized anxiety disorder with functional digestive disorders / IBS
  • Mixed methods analysis of cognitive debriefing data in irritable bowel syndrome with constipation or chronic constipation (IBS-C/CC)
  • PRO dossier in IBS-C
  • Independent analysis, evidence saturation and report on 30 interviews in IBS-C
  • Development of a PRO strategy for paediatric IBS-C
  • Literature review in IBS-C
  • Manuscript based on the findings of the exit interview study of patients taking a treatment for IBS-C within a long term safety study
  • Exploratory analysis of PRO data to support the interpretation of change on IBS-C abdominal symptom endpoints
  • Development of PRO instruments assessing symptoms and health related quality of life for paediatric patients with IBS-C
  • Testing and cognitive debriefing interviews for a diary in paediatric symptoms of IBS-C/CC
  • Network meta-analysis of treatments for IBC-C/CC
  • Conference poster and debriefing of paediatric IBS-C
  • Cognitive debriefing of a PRO measure of IBS-C symptoms
  • Long term safety study and participation interviews in IBS-C
  • Consultation on a project on IBS-C
  • FDA meeting on IBS-C
  • Interviews with clinicians to understand diagnoses of paediatric IBS-C
  • Development and validation of a primary endpoint to support an indication in irritable bowel syndrome with diarrhoea (IBS-D)
  • Psychometric validation of a newly developed PRO for IBS-D
  • Analysis of qualitative data on IBS-D from focus groups
  • Psychometric validation for a newly developed PRO in IBS-D
  • Development of a PRO measurement dossier on IBS-D for submission to the FDA
  • Development of a PRO instrument assessing symptoms in paediatric patients with IBS-D
  • Assistance with preparations for an FDA type C meeting on IBS-D
  • Development and validation of a primary endpoint for an FDA submission in IBS-D
  • Selection of PROs for IBS-D, regulatory strategy and support
  • Phase II data analysis: Interim and final psychometric testing in IBS-D
  • Manuscript on IBS-C and IBS-D

Kidney cancer / Renal cell carcinoma

  • Landscape analysis for ablation in kidney cancer
  • Burden of disease deck in renal cell carcinoma
  • Market access payer value tool in renal cell carcinoma
  • Analyses of endpoints in oncology: Statistical analyses in renal cell carcinoma
  • Updates to a Health Impact Projection (HIP) model in locally advanced or metastatic renal cell carcinoma
  • Analyses of endpoints in oncology: Country-specific EQ-5D utilities in renal cell carcinoma
  • Clinical trial analyses to support health-related quality of life in renal cell carcinoma: Ad hoc analyses and Q&A document
  • Quick review of PRO measures for a phase II trial in renal cell carcinoma
  • General consultancy agreement to review two PRO measures in renal cell carcinoma to support labelling claims with the FDA and EMA
  • Utilities analyses to support economic modelling in renal cell carcinoma
  • Value tool for decision making in renal cell carcinoma
  • e-v@luate platforms in renal cell carcinoma
  • Summary presentation of a workstream in renal disease
  • Caregiver burden in renal cell carcinoma in the EU
  • Scientific communication of a systematic literature review on caregiver burden in renal cell carcinoma

Kidney (renal) disease

  • Core value dossier for a treatment used in stages III, IV and V renal disease
  • Core value dossier in the treatment of secondary hyperparathyroidism associated with chronic kidney disease including end stage renal disease
  • Core value dossier in chronic kidney disease and end stage renal disease
  • Literature review of the burden of depression in hemodialysis patients (in chronic kidney disease)
  • Pilot utility elicitation study in end stage renal disease
  • Logistical costs of changing treatment in chronic kidney disease
  • Capturing costs when switching from one ESA to another for chronic kidney disease in UK hospital trusts
  • Payer research to understand potential pricing and reimbursement in polycystic kidney disease
  • Kidney transplant pricing research
  • Disease area review, burden of illness and unmet needs in heart failure (and associated renal dysfunction)
  • Meta-analysis of a treatment for chronic kidney disease: trials and PRO endpoints
  • Manuscripts and conference attendance for a treatment in chronic kidney disease
  • FDA meeting support in defence of PRO claims for a treatment for chronic kidney disease
  • Manuscript and advisory board on physical functioning in chronic kidney disease
  • Development of a manuscript and production of two posters on the symptoms of chronic kidney disease when treated with a specific drug
  • Review of a dossier in chronic kidney disease
  • Qualitative interviews, conceptual model and strategic consulting on autosomal dominant polycystic kidney disease (ADPKD)
  • Measures for use in patients with autosomal dominant polycystic kidney and liver disease: development and validation of a symptom measure and validation of a health survey
  • Regulatory consulting on claims with the FDA for a treatment for end stage renal disease (ESRD)
  • Relevance and context of information for a treatment for hyperphosphatemia in patients with chronic kidney disease
  • Preparation of a manuscript on the relevance of pharmacoeconomics studies in renal disease
  • Literature research and assessment of the appetite and activities of daily living in patients with end-stage renal disease

Leukaemia

  • Exploring physicians’ perceptions of adherence levels, reasons for non-adherence, and opinions of how to improve adherence in leukaemia patients receiving treatment
  • Patient satisfaction in chemotherapy for leukaemia

Acute lymphoblastic leukaemia

  • Support in IRB submissions and scientific dissemination in acute lymphoblastic leukaemia
  • Burden of refractory acute lymphoblastic leukaemia on patients and caregivers

Acute myeloid leukaemia (AML)

  • Global value dossier and e-v@luate platform for a treatment in AML
  • Global value dossier, conference poster and medical writing support in AML
  • Quality of life analysis in the treatment of AML
  • Payer evidence council value communication materials (booklet, slides and Q&A) to inform phase III trial design in AML
  • Cost-effectiveness analysis and budget impact analysis for a prognostic and minimal residual genetic tests for AML
  • Systematic literature review of healthcare resource utilisation in AML
  • Literature review of resource utilisation in AML
  • Strategic consulting on AML
  • Health-related quality of life in elderly patients with AML: Position paper on an AML treatment for inclusion in a value dossier
  • Qualitative research to understand the value of extended overall survival to AML patients

Chronic lymphocytic leukaemia (CLL)

  • Utility study in advanced CLL
  • Abstract and manuscript on utility study results in CLL
  • Payer evidence dossiers for treatments of CLL
  • Mixed treatment comparison and training meeting on a global value dossier for a treatment for CLL
  • Health state preference study mapping the change over the course of the CLL disease process
  • Conference poster on the health state preference study mapping the change over the course of the CLL disease process
  • Global value dossier for a treatment in CLL
  • Statistical analysis plans and provision of PRO support to the client for their trials of a biological therapy cancer treatment for CLL
  • General consultancy agreement to review PRO measures in CLL
  • Analysis of PRO data from the CLL registry
  • Manuscript on a budget impact model for a cross-indication biosimilar in CLL

Chronic myeloid leukaemia (CML)

  • Value dossier support in CML linking myelosuppression with quality of life impact
  • Value dossier support in CML linking response to utilities and additional analysis
  • Critical review of PRO instruments in CML
  • Adverse event to PRO linking in CML
  • Manuscript on AE-PRO linking in CML
  • Targeted literature review and manuscript on factors associated with adherence in CML
  • Development of a link between side effects and PROs in CML – a univariate approach

Literature reviews

We have a dedicated team of experts with vast experience in literature reviews and research, able to address client challenges and steer your product towards market access success. Our experience of systematic and structured literature reviews covers a wide range of therapeutic indications and topics including:

Structured literature reviews

  • Acne
  • Acromegaly
  • Actinic keratosis
  • Acute bacterial skin and skin structure infections (ABSSSI)
  • Acute myocardial infarction
  • Adrenoleukodystrophy
  • Alcohol dependency
  • Allergic rhinitis
  • Allergies
  • Alzheimer’s disease
  • Ankylosing spondylitis
  • Arthritis
  • Atypical haemolytic uremic syndrome (aHUS)
  • Asthma
  • Asthma COPD Overlap Syndrome (ACOS)
  • Benign prostatic hyperplasia
  • Breast cancer
  • Cervical cancer
  • Chronic obstructive pulmonary disease (COPD)
  • Colorectal cancer
  • Constipation (and chronic constipation)
  • Cough and cold
  • Crohn’s disease
  • Dementia
  • Depression
  • Diabetes (type 2)
  • Diptheria
  • Down’s syndrome
  • Dry eye
  • Dystrophic epidermolysis bullosa
  • Epilepsy
  • Fabry disease
  • Fibromyalgia
  • Fragile X syndrome
  • Gastric cancer
  • Gastric reflux
  • Glioblastoma
  • Glucose transporter type 1 deficiency syndrome
  • Group B streptococcus
  • Growth hormone deficiency
  • Haemophilia A and B
  • Hand eczema
  • Head and neck cancer
  • Heart disease
  • Hepatitis A and C
  • Herpes zoster/shingles
  • Hidradenitis suppurativa
  • HIV and AIDS
  • HPV
  • HRT outcomes in the menopause
  • Hypogonadism
  • Hypoparathyroidism
  • Idiopathic pulmonary fibrosis
  • Immune thrombocytopenia
  • Infertility
  • Influenza
  • Insomnia
  • Interstitial cystitis
  • Interstitial lung disease in systemic sclerosis (SSc-ILD)
  • Irritable bowel syndrome
  • Kidney cancer
  • Kidney disease / kidney failure
  • Leukaemia
  • Lipid modification
  • Liver cancer
  • Lower limb spasticity
  • Lung cancer (small cell and non-small cell)
  • Lupus (systemic lupus erythematosus and lupus nephritis)
  • Lymphomas
  • Macular degeneration
  • Melanoma
  • Migraine
  • Mucopolysaccharidosis I (MPS I)
  • Myocardial infarction
  • Neural tube defects
  • Nonalcoholic steatohepatitis (NASH)
  • Osteoarthritis
  • Osteomyelitis
  • Ovarian cancer
  • Pain (including chronic pain and trauma pain)
  • Parkinson’s disease
  • Peripheral artery disease
  • Peripheral diabetic neuropathy
  • Pertussis
  • Phenylketonuria
  • Polio
  • Post-herpetic neuralgia
  • Post-operative ileus
  • Prostate cancer
  • Psoriasis
  • Rabies
  • Retinitis pigmentosa
  • Retinopathy of prematurity
  • Rheumatoid arthritis
  • Schizophrenia
  • Sjögren’s syndrome
  • Smoking cessation
  • Stroke
  • Tetanus
  • Typhoid
  • Ulcerative colitis
  • Wheezing
  • Yellow fever

Systematic literature reviews

  • Asthma
  • Bipolar disorder
  • Chemotherapy-induced anaemia
  • Epilepsy
  • Hepatitis B
  • Herpes zoster/shingles
  • HPV
  • Leukaemia
  • Lung cancer (small cell and non-small cell)
  • Lymphomas
  • Melanoma
  • Post-herpetic neuralgia
  • Prostate cancer
  • Psoriasis
  • Psoriatic arthritis
  • Pulmonary arterial hypertension
  • Renal cell carcinoma

Liver cancer

  • Development of a HEOR strategy for treatment of hepatocellular cancer
  • Clinical trial analyses to support health-related quality of life in advanced hepatocellular carcinoma
  • Updates to a Health Impact Projection (HIP) model in hepatocellular carcinoma
  • Landscape analysis for ablation in liver cancer

Long-chain fatty acid oxidation disorders

  • Qualitative research to explore and support the assessment of the patient experience and impact on functioning of long-chain fatty acid oxidation disorders
  • Qualitative interviews on long-chain fatty acid oxidation disorders

Lower urinary tract symptoms

  • Cognitive debriefing interviews on the symptom assessment goal achievement questionnaire on lower urinary tract symptoms in the UK, Germany and Spain
  • Data analysis and communication activities on Self-Assessment Goal Achievement (SAGA) in lower urinary tract symptoms

Lung cancer

  • Preparation of 3 existing manuscripts on lung cancer for submission
  • Literature search and analysis of phase 2 vs phase 3 lung cancer studies
  • Literature and reimbursement review of intravenous versus subcutaneous therapies in lung cancer
  • Development of a pan-lung oncology treatment model
  • Landscape analysis for ablation in lung cancer
  • Patient interviews in lung cancer
  • Analyses of endpoints in oncology: Statistical analyses in lung cancer
  • Analyses of endpoints in oncology: Country-specific EQ-5D utilities in lung cancer
  • Analytical evidence for improvement in symptoms and quality of life in lung cancer patients on a specified treatment
  • Analytical evidence for improvement in symptoms and quality of life in pre and post-randomisation lung cancer patients (by age groups)
  • Strategic consulting, research and measurement in solid tumours
  • Strategic communications planning in lung cancer
  • Consulting for an FDA submission in lung cancer
  • Summary presentation of a workstream in lung cancer
  • Updates to a Health Impact Projection (HIP) model in extensive 1st line SCLC, locally advanced or metastatic 2nd line NSCLC, and metastatic 1st line NSCLC

Non-small cell lung cancer (NSCLC)

  • Global value dossier and e-v@luate platform in NSCLC
  • Global value dossier and e-v@luate platform in non-squamous NSCLC
  • Global value dossier and e-v@luate platform in advanced squamous NSCLC
  • Global value dossier for a treatment in metastatic NSCLC
  • Payer value deck and response to payer questions update in 1st line NSCLC
  • Updated payer value dossier deck and FAQs deck for 1st line NSCLC
  • Updated burden of disease decks, payer value dossier decks and FAQs decks for 1st line and 2nd line NSCLC
  • Societal costs, health-related quality of life systematic literature review and publications plan for NSCLC in Europe
  • Literature review of overall survival and bone metastases in NSCLC
  • Literature review to inform global market access materials in NSCLC
  • Structured literature review in advanced 1st line NSCLC
  • Systematic review and mixed treatment comparison in advanced NSCLC
  • Development of technical documentation and manuscript on NSCLC
  • Two manuscripts on the indirect comparison of the efficacy of two different therapies for NSCLC
  • Development of a manuscript on the cost-effectiveness of a treatment in NSCLC in Italy
  • Manuscript on the efficacy of three different drugs for the treatment of NSCLC
  • Model review of a drug used in the treatment of NSCLC
  • Multi-indication budget impact model in NSCLC
  • Adaptation of a multi-indication value-based pricing model in NSCLC to China
  • Value-based model in NSCLC
  • Update to a Belgian value-based pricing model in NSCLC
  • Standardisation of economic models in NSCLC
  • Global model update and country adaptations for a multi-indication value-based pricing (VBP) model on NSCLC
  • Burden of disease decks in advanced 1st line and 2nd line NSCLC
  • Burden of disease deck update in 1st line NSCLC
  • Integrated research plan in advanced melanoma and NSCLC
  • Value slide deck for treatment in NSCLC
  • Guidance documents for affiliates in treatment for NSCLC
  • Situational analysis report of epidermal growth factor receptor (EGFR) predictive testing in NSCLC
  • Communication toolkit for a lung cancer supplement
  • Companion diagnostics biomarker FAQs compilation deck in NSCLC
  • FAQs update in advanced 1st line NSCLC
  • FAQs deck update in 2nd line NSCLC
  • Payer slide decks and objection handler in NSCLC
  • Payer tools implementation guide in NSCLC
  • Payer value proposition deck update in 2nd line NSCLC
  • Payer value deck update in advanced 1st line NSCLC
  • Payer value deck and response to payer questions update in 1st line NSCLC
  • HTA submission support in epidermal growth factor receptor positive (EGFR+) and non-small cell lung cancer (NSCLC)
  • Numerous abstracts and conference posters on NSCLC, advanced NSCLC and related treatments
  • Several abstracts and conference posters relating to the cost and cost effectiveness of a first-line treatment option for patients with NSCLC
  • Abstract and poster on progression-free survival and overall survival in patients with NSCLC
  • Literature review of outcomes and costs during treatment for advanced NSCLC
  • Literature review and consultancy on NSCLC
  • Manuscript on stage IIIb and IV NSCLC
  • Development of a measurement dossier in advanced NSCLC for the EMA
  • Meta-analysis and manuscript on stage IIIb and IV NSCLC
  • Statistical analyses of clinical trial data (safety study) in NSCLC
  • Statistical analyses of clinical trial data (observational study) in NSCLC
  • Clinical trial analyses to support health-related quality of life in first-line NSCLC
  • Qualitative study on the needs and preferences of patients with advanced NSCLC for maintenance therapy
  • Development of an analysis plan in NSCLC for the USA and Europe
  • Analysis of PRO data in NSCLC
  • Qualitative interviews to understand the impact of NSCLC on quality of life and on caregivers and family members
  • EQ-5D review for an EMA measurement dossier in advanced NSCLC
  • Exploratory qualitative interviews in NSCLC patients to assess progression-free survival
  • Comparative effectiveness of two treatments for the treatment of NSCLC
  • Feasibility network meta-analysis comparison of two treatments for NSCLC
  • Exploratory analysis of the Visual Symptom Assessment Questionnaire (VSAQ) in patients who have undergone treatment for NSCLC
  • Utilities analyses to support economic modelling in NSCLC
  • Clinical trial analyses to support health-related quality of life in NSCLC
  • Impact of whole brain radiation therapy in patients with NSCLC with brain metastases

Small cell lung cancer (SCLC)

  • Global value dossier and upload to e-v@luate platform in SCLC
  • AMCP dossier in SCLC
  • Systematic literature reviews for the societal and health-related quality of life burden of SCLC
  • Systematic literature review and manuscript on real-world effectiveness and tolerability of treatments in SCLC
  • Literature review on real-world effectiveness and tolerability of treatment in SCLC
  • Utility study in SCLC
  • Development of a budget impact model in SCLC
  • Budget impact model in 1st line SCLC
  • Development of a disease conceptual model and endpoint recommendation for SCLC
  • Phase IV clinical trial analysis of two drugs used in the treatment of SCLC
  • Analysis of symptoms for a drug used to treat SCLC
  • Full text reports on the longitudinal analyses of a drug used to treat SCLC for EU submission
  • Literature and PRO strategy for SCLC
  • Clinical trial analyses to support health-related quality of life in SCLC
  • Literature review and consultancy on SCLC

Lupus and systemic lupus erythematosus

  • Manuscript on the understanding of payers and pricing in lupus nephritis
  • PRO consulting in lupus for labelling claims
  • Assessing utility for flares in systemic lupus erythematosus in the UK, France, Spain, Australia and Canada, including training and managing local interviewing agencies and providing support to local teams
  • Key opinion leader contracting and additional interviews for assessing utility in various severities of flares in systemic lupus erythematosus
  • Study on the treatment of systemic lupus erythematosus in Japan
  • Update of a literature search in systemic lupus erythematosus and lupus nephritis
  • Strategic literature review and gap analysis in systemic lupus erythematosus and lupus nephritis
  • Communication of a literature review on systemic lupus erythematosus and lupus nephritis
  • Manuscript on the health-related quality of life benefits of a treatment for systemic lupus erythematosus
  • A study of the value of simple disease activity tools to rheumatologists who treat systemic lupus erythematosus
  • Target product profile development in systemic lupus erythematosus
  • Analysis of a PRO and resource utilisation in systemic lupus erythematosus
  • Development of posters on the analysis of a PRO and resource utilisation in systemic lupus erythematosus
  • Critical review of PRO instruments in systemic lupus erythematosus and fatigue and pain in rheumatic disease

Lymphomas

B-cell lymphoma

  • Payer evidence dossiers in B-Cell lymphoma
  • Development of a budget impact model for primary mediastinal B-cell lymphoma (PMBCL)
  • Literature review and preparation of a PRO strategy in large B-cell lymphoma
  • Burden of diffuse large B-cell lymphoma on patients and caregivers
  • e-v@luate platform in diffuse large B-cell lymphoma

Hodgkin’s lymphoma

  • Payer evidence dossiers in non-Hodgkin’s lymphoma
  • Early payer engagement deck in classical Hodgkin’s lymphoma
  • Analyses of endpoints in oncology: Statistical analyses in Hodgkin’s lymphoma
  • Clinical trial analyses to support health-related quality of life in Hodgkin’s lymphoma

Non-Hodgkin’s lymphoma

  • Update of a payer evidence dossier in non-Hodgkin’s lymphoma
  • Literature review and conceptual mapping in non-Hodgkin’s lymphoma
  • Strategic PRO endpoint support, gap analysis and patient interviews in a biological therapy treatment for non-Hodgkin’s lymphoma
  • Validation of a patient satisfaction questionnaire in non-Hodgkin’s lymphoma
  • Conference poster and slide deck on non-Hodgkin’s lymphoma
  • Manuscript on a budget impact model for a cross-indication biosimilar in diffuse large B-Cell lymphoma, follicular lymphoma, follicular non-Hodgkin’s lymphoma

Lymphomas (other)

  • Core value dossier and value proposition in cutaneous T-cell lymphoma
  • Development of a budget impact tool for a treatment for chronic lymphatic lymphoma for Spain
  • Support programme for reimbursement submissions in cutaneous T-cell lymphoma
  • Strategic consulting for a lymphoma trial
  • Clinical trial analysis of health-related quality of life data in patients with previously untreated follicular lymphoma
  • Manuscript on a budget impact model for a cross-indication biosimilar in diffuse large B-Cell lymphoma, follicular lymphoma, and follicular non-Hodgkin’s lymphoma